MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum Disorder

뉴스 본문을 불러오고 있어요.

MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum Disorder | 웨이프 WAPE

MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Spectrum Disorder; Trial Did Not Meet Its Primary Endpoint In Social Communication Deficits Associated With Autism Spectrum Disorder

기사 요약

관련 종목

댓글 —